ELEDON PHARMACEUTICALS INC

Explore why Eledon Pharmaceuticals’ modest rally may signal a temporary rebound and what regulatory milestones could spark a breakout above its 52‑week high.

Explore Eledon Pharmaceuticals’ breakthrough: a new islet‑cell transplant trial for type‑1 diabetes with kidney disease, promising safer immunosuppression and wider patient access.

ELDN’s share price jumps 4.4% after a month‑long decline, signaling renewed investor optimism in its clinical‑stage biotech strategy targeting the CD40L pathway.